<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03055832</url>
  </required_header>
  <id_info>
    <org_study_id>2020-03</org_study_id>
    <nct_id>NCT03055832</nct_id>
  </id_info>
  <brief_title>Comparison Between iLux™ and LipiFlow® in the Treatment of Meibomian Gland Dysfunction</brief_title>
  <official_title>Randomized Comparison Between iLux™ and LipiFlow® in the Treatment of Meibomian Gland Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tear Film Innovations, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tear Film Innovations, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to compare changes in meibomian gland dysfunction (MGD), tear
      break-up time (TBT) and evaporative dry eye (EDE) symptoms after treatment with either the
      iLux® 2020 System or the LipiFlow® Thermal Pulsation System.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      At the Baseline visit (Day 0), subjects were assessed pre-treatment, during treatment, and
      post-treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 9, 2017</start_date>
  <completion_date type="Actual">July 20, 2017</completion_date>
  <primary_completion_date type="Actual">July 20, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Meibomian gland score will be assessed by a masked rater</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline to Week 4 in Meibomian Gland Score (MGS)</measure>
    <time_frame>Baseline, Week 4</time_frame>
    <description>Meibomian glands on the lower eyelid were assessed by the examiner using a Meibomian Gland Evaluator while viewing the eyelid margin using a slit lamp microscope. 5 glands in 3 zones (nasal, medial, temporal) were evaluated. Each gland was scored from 0-3 for a maximum MGS of 45 in each eye. MGS scoring was as follows: 0 = no secretion (worst), 1 = inspissated, 2 = cloudy, 3 = clear liquid (best). A positive change value indicates an improvement.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline to Week 4 in Tear Break-Up Time (TBT)</measure>
    <time_frame>Baseline, Week 4</time_frame>
    <description>Tear break-up time (defined as the time required for dry spots to appear on the surface of the eye after blinking) was assessed by the examiner using a slit lamp and fluorescein strips. Fluorescein was instilled onto the patient's eye, after which the patient blinked three times, then kept the eye open. Immediately thereafter, the examiner used a stopwatch to record the time between the last blink and the first appearance of a dark spot on the cornea (formation of dry area). Three consecutive measurements were taken and averaged for actual TBT. A positive change value represents a lengthening in the tear break-up time and greater comfort.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence (Number) of Device- or Procedure-related Adverse Events</measure>
    <time_frame>Week 4</time_frame>
    <description>The number of device- or procedure-related adverse events was calculated, including changes from baseline (Yes/No) in any of the following eyelid characteristics: lid margin assessment or development of floppy eyelids or entropion (eyelid rolled inward) or ectropion (eyelid sagging outward) or loss of lash integrity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 4 in Ocular Surface Disease Index (OSDI)</measure>
    <time_frame>Baseline, Week 4</time_frame>
    <description>The Ocular Surface Disease Index (OSDI) is a 12-item, patient-reported outcome questionnaire used to measure ocular symptoms, visual function, and environmental factors that may affect a patient's vision. Each item is scored on a 0-4 Likert-type scale, where 0 is &quot;None&quot; and 4 is &quot;All of the Time.&quot; The OSDI is calculated as the (sum of scores) x 25 / (# of questions answered), for a resultant overall score of 0-100, where 0 corresponds to no disability and 100 corresponds to complete disability. A negative change value indicates an improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Pain Score During Treatment</measure>
    <time_frame>Baseline (Day 0), Immediately Post-Treatment (Day 0), Day 1 Post-Treatment</time_frame>
    <description>The patient placed a vertical line on visual analog scale questionnaire using a scale of 0-100 (0 = no pain, 100 = maximum pain) at the point that indicated the pain in or around their eyelids, or face during the procedure including feelings of pressure, tightness, heaviness, burning, and other negative sensations. A score a 20 was associated with a description of &quot;hurts a little&quot;. Assessments were made at baseline (pre-treatment), immediately post-treatment, and Day 1 post-treatment. No formal hypothesis testing was pre-specified for this endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Discomfort Score During Treatment</measure>
    <time_frame>Baseline (Day 0), Immediately Post-Treatment (Day 0), Day 1 Post-Treatment</time_frame>
    <description>The patient placed a vertical line on visual analog scale questionnaire using a scale of 0-100 (0 = no discomfort, 100 = maximum discomfort) at the point that indicated the discomfort in or around their eyelids, or face during the procedure including feelings of pressure, tightness, heaviness, burning, and other negative sensations. Assessments were made at baseline (pre-treatment), immediately post-treatment, and Day 1 post-treatment. No formal hypothesis testing was pre-specified for this endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Post-Treatment in Ocular Surface Staining</measure>
    <time_frame>Baseline (Day 0), Immediately Post-Treatment (Day 0), Day 1 Post-Treatment</time_frame>
    <description>Corneal staining was assessed by the examiner using the National Eye Institute corneal grading scale and a slit-lamp. Each of the 5 corneal regions (superior, inferior, central, temporal, &amp; central), was graded on a 0-3 scale, where 0=normal-no staining (best); 1=mild-superficial stippling micropunctate staining; 2=moderate-macropunctate staining with some coalescent areas; and 3=severe-numerous coalescent macropunctate areas and/or patches (worst). The scores were summed for each eye, and an overall corneal staining score was computed as the average of the sum from both eyes. Overall scores ranged between 0-15, with higher change value indicating greater damage to the corneal surface. Assessments were made at baseline (pre-treatment), immediately post-treatment, and Day 1 post-treatment. No formal hypothesis testing was pre-specified for this endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Post-Treatment in Intraocular Pressure (IOP)</measure>
    <time_frame>Baseline (Day 0), Immediately Post-Treatment (Day 0)</time_frame>
    <description>IOP (fluid pressure inside the eye) was measured by Goldmann applanation tonometry. A higher IOP can be a greater risk for developing glaucoma or glaucoma progression (leading to optic nerve damage). A negative change value indicates an improvement. No formal hypothesis testing was pre-specified for this endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Post-Treatment in Best Spectacle-Corrected Visual Acuity (BSCVA)</measure>
    <time_frame>Baseline (Day 0), Immediately Post-Treatment (Day 0)</time_frame>
    <description>Visual acuity was assessed with spectacles or other visual corrective devices in place using Early Treatment Diabetic Retinopathy Study (ETDRS) charts. Results are presented in logarithm of the minimum angle of resolution (logMAR) with 0.2 in logMAR corresponding to 10 ETDRS letters read. A lower logMAR change value indicates an improvement in visual acuity. No formal hypothesis testing was pre-specified for this endpoint.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">142</enrollment>
  <condition>Meibomian Gland Dysfunction</condition>
  <arm_group>
    <arm_group_label>iLux 2020 System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Meibomian gland treatment (Day 0) according to instructions for use (IFU)/User Manual</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LipiFlow Thermal Pulsation System</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Meibomian gland treatment (Day 0) according to instructions for use (IFU)/User Manual</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>iLux 2020 System</intervention_name>
    <description>Medical device that applies localized heat and pressure therapy to the eyelid in order to express melted meibum from obstructed glands</description>
    <arm_group_label>iLux 2020 System</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>LipiFlow Pulsation System</intervention_name>
    <description>Medical device that applies a combination of heat and pressure to the inner eyelid to remove gland obstructions and stagnant gland content</description>
    <arm_group_label>LipiFlow Thermal Pulsation System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years and older of any gender or race

          -  Written informed consent to participate in the study

          -  Willingness and ability to return for all study visits

          -  Positive history of self-reported dry eye symptoms for three months prior to the study
             using OSDI with a score of ≥ 23 at the baseline visit

          -  Evidence of meibomian gland (MG) obstruction, based on total MGS of ≤12 in lower
             eyelids for each eye as assessed by a clinician not involved in the study procedure

          -  Tear break-up time &lt;10 seconds

          -  Agreement/ability to abstain from dry eye/MGD medications for the time between the
             screening visit and the final study visit (ocular lubricants are allowed if no changes
             are made during the study)

        Exclusion Criteria:

          -  History of ocular or corneal surgery including intraocular, oculo-plastic, corneal or
             refractive surgery within 1 year

          -  Subjects with giant papillary conjunctivitis

          -  Subject with punctal plugs or who have had punctal cautery

          -  Ocular injury or trauma, chemical burns, or limbal stem cell deficiency within 3
             months of the baseline examination

          -  Active ocular herpes zoster or simplex of eye or eyelid or a history of these within
             the last 3 months

          -  Subjects who are aphakic

          -  Cicatricial lid margin disease identified via slit lamp examination, including
             pemphigoid, symblepharon, etc.

          -  Active ocular infection

          -  Active ocular inflammation or history of chronic, recurrent ocular inflammation within
             prior 3 months

          -  Ocular surface abnormality that may compromise corneal integrity

          -  Lid surface abnormalities that affect lid function in either eye

          -  Anterior blepharitis (staphylococcal, demodex or seborrheic grade 3 or 4)

          -  Systemic disease conditions that cause dry eye

          -  Unwillingness to abstain from systemic medications known to cause dryness for the
             study duration

          -  Women who are pregnant, nursing, or not utilizing adequate birth control measures

          -  Individuals who have either changed the dosing of systemic medications or non-dry
             eye/MGD ophthalmic medications within the past 30 days prior to screening

          -  Individuals who are unable or unwilling to remain on a stable dosing regimen for the
             duration of the study

          -  Individuals using isotretinoin (Accutane) within 1 year, cyclosporine-A (Restasis) or
             lifitegrast ophthalmic solution 5% (Xiidra) within 3 months, or any other dry eye or
             MGD medications within 2 weeks of screening (ocular lubricants are allowed if no
             changes are made during the study)

          -  Individuals wearing contact lenses at any time during the prior three months or during
             the study period

          -  Eyelid tattoos, including permanent eyeliner makeup

          -  Individuals that were treated with LipiFlow in either eye in the last 24 months

          -  Individuals using another ophthalmic investigational device or agent within 30 days of
             study participation

          -  Individuals who are unable to complete the required patient questionnaires in English
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>TearFilm Investigative Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TearFilm Investigative Site</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>95260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TearFilm Investigative Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TearFilm Investigative Site</name>
      <address>
        <city>Centennial</city>
        <state>Colorado</state>
        <zip>80112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TearFilm Investigative Site</name>
      <address>
        <city>Greenwood Village</city>
        <state>Colorado</state>
        <zip>80111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TearFilm Investigative Site</name>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <zip>63017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TearFilm Investigative Site</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>February 10, 2017</study_first_submitted>
  <study_first_submitted_qc>February 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 16, 2017</study_first_posted>
  <results_first_submitted>April 22, 2019</results_first_submitted>
  <results_first_submitted_qc>April 22, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 20, 2019</results_first_posted>
  <last_update_submitted>May 20, 2019</last_update_submitted>
  <last_update_submitted_qc>May 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>iLux</keyword>
  <keyword>LipiFlow</keyword>
  <keyword>dry eye</keyword>
  <keyword>Meibomian Gland Dysfunction</keyword>
  <keyword>evaporative dry eye</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 3, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/32/NCT03055832/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>iLux 2020 System</title>
          <description>Meibomian gland treatment (Day 0) according to instructions for use (IFU)/User Manual</description>
        </group>
        <group group_id="P2">
          <title>LipiFlow Thermal Pulsation System</title>
          <description>Meibomian gland treatment (Day 0) according to instructions for use (IFU)/User Manual</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Baseline</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="71"/>
                <participants group_id="P2" count="71"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="71"/>
                <participants group_id="P2" count="71"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Immediately Post-Procedure (Hour 1)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="71"/>
                <participants group_id="P2" count="71"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="71"/>
                <participants group_id="P2" count="71"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Day 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="71"/>
                <participants group_id="P2" count="71"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="71"/>
                <participants group_id="P2" count="71"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Week 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="71"/>
                <participants group_id="P2" count="71"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
                <participants group_id="P2" count="71"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Week 4</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
                <participants group_id="P2" count="71"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
                <participants group_id="P2" count="71"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>iLux 2020 System</title>
          <description>Meibomian gland treatment (Day 0) according to instructions for use (IFU)/User Manual</description>
        </group>
        <group group_id="B2">
          <title>LipiFlow Thermal Pulsation System</title>
          <description>Meibomian gland treatment (Day 0) according to instructions for use (IFU)/User Manual</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="71"/>
            <count group_id="B2" value="71"/>
            <count group_id="B3" value="142"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Under 18 Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18 Years and Older</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="71"/>
                    <measurement group_id="B3" value="142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="101"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="129"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="71"/>
                    <measurement group_id="B3" value="142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to Week 4 in Meibomian Gland Score (MGS)</title>
        <description>Meibomian glands on the lower eyelid were assessed by the examiner using a Meibomian Gland Evaluator while viewing the eyelid margin using a slit lamp microscope. 5 glands in 3 zones (nasal, medial, temporal) were evaluated. Each gland was scored from 0-3 for a maximum MGS of 45 in each eye. MGS scoring was as follows: 0 = no secretion (worst), 1 = inspissated, 2 = cloudy, 3 = clear liquid (best). A positive change value indicates an improvement.</description>
        <time_frame>Baseline, Week 4</time_frame>
        <population>All randomized and treated patients</population>
        <group_list>
          <group group_id="O1">
            <title>iLux Right Eye</title>
            <description>Right Eye of Subjects treated with the iLux 2020 System</description>
          </group>
          <group group_id="O2">
            <title>iLux Left Eye</title>
            <description>Left Eye of Subjects treated with the iLux 2020 System</description>
          </group>
          <group group_id="O3">
            <title>iLux Both Eyes</title>
            <description>Both Eyes of Subjects treated with the iLux 2020 System</description>
          </group>
          <group group_id="O4">
            <title>LipiFlow Right Eye</title>
            <description>Right Eye of Subjects Treated with the LipiFlow Thermal Pulsation System</description>
          </group>
          <group group_id="O5">
            <title>LipiFlow Left Eye</title>
            <description>Left Eye of Subjects treated with Lipiflow Thermal Pulsation System</description>
          </group>
          <group group_id="O6">
            <title>LipiFlow Both Eyes</title>
            <description>Both Eyes of Subjects treated with the LipiFlow Thermal Pulsation System</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 4 in Meibomian Gland Score (MGS)</title>
          <description>Meibomian glands on the lower eyelid were assessed by the examiner using a Meibomian Gland Evaluator while viewing the eyelid margin using a slit lamp microscope. 5 glands in 3 zones (nasal, medial, temporal) were evaluated. Each gland was scored from 0-3 for a maximum MGS of 45 in each eye. MGS scoring was as follows: 0 = no secretion (worst), 1 = inspissated, 2 = cloudy, 3 = clear liquid (best). A positive change value indicates an improvement.</description>
          <population>All randomized and treated patients</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="70"/>
                <count group_id="O4" value="70"/>
                <count group_id="O5" value="71"/>
                <count group_id="O6" value="71"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="140"/>
                <count group_id="O4" value="70"/>
                <count group_id="O5" value="71"/>
                <count group_id="O6" value="141"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.3" spread="12.1"/>
                    <measurement group_id="O2" value="18.0" spread="12.2"/>
                    <measurement group_id="O3" value="17.7" spread="12.2"/>
                    <measurement group_id="O4" value="18.1" spread="10.8"/>
                    <measurement group_id="O5" value="16.9" spread="11.5"/>
                    <measurement group_id="O6" value="17.5" spread="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>This study provides a combined power of co-primary endpoints of 88% given the following primary endpoint assumptions:
MGS non-inferiority delta of 5 points and standard deviation of 8 points provides power of 93.9%
TBT non-inferiority delta of 2.5 seconds and standard deviation of 4 seconds, provides a TBT primary endpoint power of 93.9%
Power that both endpoitns are significant, assuming independence was 0.939^2 = 0.882 or 88.2% power.</non_inferiority_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.13</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.88</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.82</ci_lower_limit>
            <ci_upper_limit>3.56</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to Week 4 in Tear Break-Up Time (TBT)</title>
        <description>Tear break-up time (defined as the time required for dry spots to appear on the surface of the eye after blinking) was assessed by the examiner using a slit lamp and fluorescein strips. Fluorescein was instilled onto the patient's eye, after which the patient blinked three times, then kept the eye open. Immediately thereafter, the examiner used a stopwatch to record the time between the last blink and the first appearance of a dark spot on the cornea (formation of dry area). Three consecutive measurements were taken and averaged for actual TBT. A positive change value represents a lengthening in the tear break-up time and greater comfort.</description>
        <time_frame>Baseline, Week 4</time_frame>
        <population>All randomized and treated patients</population>
        <group_list>
          <group group_id="O1">
            <title>iLux Right Eye</title>
            <description>Right Eye of Subjects treated with the iLux 2020 System</description>
          </group>
          <group group_id="O2">
            <title>iLux Left Eye</title>
            <description>Left Eye of Subjects treated with the iLux 2020 System</description>
          </group>
          <group group_id="O3">
            <title>iLux Both Eyes</title>
            <description>Both Eyes of Subjects treated with the iLux 2020 System</description>
          </group>
          <group group_id="O4">
            <title>LipiFlow Right Eye</title>
            <description>Right Eye of Subjects Treated with the LipiFlow Thermal Pulsation System</description>
          </group>
          <group group_id="O5">
            <title>LipiFlow Left Eye</title>
            <description>Left Eye of Subjects treated with Lipiflow Thermal Pulsation System</description>
          </group>
          <group group_id="O6">
            <title>LipiFlow Both Eyes</title>
            <description>Both Eyes of Subjects treated with the LipiFlow Thermal Pulsation System</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 4 in Tear Break-Up Time (TBT)</title>
          <description>Tear break-up time (defined as the time required for dry spots to appear on the surface of the eye after blinking) was assessed by the examiner using a slit lamp and fluorescein strips. Fluorescein was instilled onto the patient's eye, after which the patient blinked three times, then kept the eye open. Immediately thereafter, the examiner used a stopwatch to record the time between the last blink and the first appearance of a dark spot on the cornea (formation of dry area). Three consecutive measurements were taken and averaged for actual TBT. A positive change value represents a lengthening in the tear break-up time and greater comfort.</description>
          <population>All randomized and treated patients</population>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="70"/>
                <count group_id="O4" value="71"/>
                <count group_id="O5" value="71"/>
                <count group_id="O6" value="71"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="140"/>
                <count group_id="O4" value="71"/>
                <count group_id="O5" value="71"/>
                <count group_id="O6" value="142"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.86" spread="3.72"/>
                    <measurement group_id="O2" value="2.73" spread="3.72"/>
                    <measurement group_id="O3" value="2.79" spread="3.66"/>
                    <measurement group_id="O4" value="2.69" spread="3.31"/>
                    <measurement group_id="O5" value="2.61" spread="3.22"/>
                    <measurement group_id="O6" value="2.65" spread="3.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>This study provides a combined power of co-primary endpoints of 88% given the following primary endpoint assumptions:
MGS non-inferiority delta of 5 points and standard deviation of 8 points provides power of 93.9%
TBT non-inferiority delta of 2.5 seconds and standard deviation of 4 seconds, provides a TBT primary endpoint power of 93.9%
Power that both endpoitns are significant, assuming independence was 0.939^2 = 0.882 or 88.2% power.</non_inferiority_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.10</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.54</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.97</ci_lower_limit>
            <ci_upper_limit>1.16</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence (Number) of Device- or Procedure-related Adverse Events</title>
        <description>The number of device- or procedure-related adverse events was calculated, including changes from baseline (Yes/No) in any of the following eyelid characteristics: lid margin assessment or development of floppy eyelids or entropion (eyelid rolled inward) or ectropion (eyelid sagging outward) or loss of lash integrity.</description>
        <time_frame>Week 4</time_frame>
        <population>All randomized and treated patients</population>
        <group_list>
          <group group_id="O1">
            <title>iLux 2020 System</title>
            <description>Meibomian Gland Treatment
iLux 2020 System: Heating and compression to express clogged meibomian glands</description>
          </group>
          <group group_id="O2">
            <title>LipiFlow Thermal Pulsation System</title>
            <description>Meibomian Gland Treatment
LipiFlow Pulsation System: Heating and compression to express clogged meibomian glands</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence (Number) of Device- or Procedure-related Adverse Events</title>
          <description>The number of device- or procedure-related adverse events was calculated, including changes from baseline (Yes/No) in any of the following eyelid characteristics: lid margin assessment or development of floppy eyelids or entropion (eyelid rolled inward) or ectropion (eyelid sagging outward) or loss of lash integrity.</description>
          <population>All randomized and treated patients</population>
          <units>Adverse event</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>A formal hypothesis was not proposed for this endpoint and therefore a power calculation was not performed. A Fisher's Exact test was performed post hoc to determine if a significant difference existed between the two arms.</non_inferiority_desc>
            <p_value>0.12</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 4 in Ocular Surface Disease Index (OSDI)</title>
        <description>The Ocular Surface Disease Index (OSDI) is a 12-item, patient-reported outcome questionnaire used to measure ocular symptoms, visual function, and environmental factors that may affect a patient's vision. Each item is scored on a 0-4 Likert-type scale, where 0 is &quot;None&quot; and 4 is &quot;All of the Time.&quot; The OSDI is calculated as the (sum of scores) x 25 / (# of questions answered), for a resultant overall score of 0-100, where 0 corresponds to no disability and 100 corresponds to complete disability. A negative change value indicates an improvement.</description>
        <time_frame>Baseline, Week 4</time_frame>
        <population>All randomized and treated patients</population>
        <group_list>
          <group group_id="O1">
            <title>iLux All Questions</title>
            <description>All OSDI questions in Subjects treated with the iLux 2020 System</description>
          </group>
          <group group_id="O2">
            <title>iLux Vision Questions</title>
            <description>OSDI Questions 1-5 in Subjects Treated with the iLux 2020 System</description>
          </group>
          <group group_id="O3">
            <title>iLux Ocular Questions</title>
            <description>OSDI questions 6-9 in Subjects treated with the iLux 2020 System</description>
          </group>
          <group group_id="O4">
            <title>iLux Trigger Questions</title>
            <description>OSDI questions 10-12 in Subjects treated with the iLux 2020 System</description>
          </group>
          <group group_id="O5">
            <title>LipiFlow All Questions</title>
            <description>All OSDI questions (1-12) in Subjects treated with the LipiFlow Thermal Pulsation System</description>
          </group>
          <group group_id="O6">
            <title>LipiFlow Vision Questions</title>
            <description>OSDI Questions 1-5 in Subjects treated with the LipiFlow Thermal Pulsation System</description>
          </group>
          <group group_id="O7">
            <title>LipiFlow Ocular Questions</title>
            <description>OSDI questions 6-9 in Subjects treated with the LipiFlow Thermal Pulsation System</description>
          </group>
          <group group_id="O8">
            <title>LipiFlow Trigger Questions</title>
            <description>OSDI questions 10-12 in Subjects treated with the LipiFlow Thermal Pulsation System</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 4 in Ocular Surface Disease Index (OSDI)</title>
          <description>The Ocular Surface Disease Index (OSDI) is a 12-item, patient-reported outcome questionnaire used to measure ocular symptoms, visual function, and environmental factors that may affect a patient's vision. Each item is scored on a 0-4 Likert-type scale, where 0 is &quot;None&quot; and 4 is &quot;All of the Time.&quot; The OSDI is calculated as the (sum of scores) x 25 / (# of questions answered), for a resultant overall score of 0-100, where 0 corresponds to no disability and 100 corresponds to complete disability. A negative change value indicates an improvement.</description>
          <population>All randomized and treated patients</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="70"/>
                <count group_id="O4" value="70"/>
                <count group_id="O5" value="71"/>
                <count group_id="O6" value="71"/>
                <count group_id="O7" value="70"/>
                <count group_id="O8" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31.0" spread="18.4"/>
                    <measurement group_id="O2" value="-27.3" spread="19.7"/>
                    <measurement group_id="O3" value="-30.9" spread="25.9"/>
                    <measurement group_id="O4" value="-37.0" spread="30.6"/>
                    <measurement group_id="O5" value="-28.0" spread="22.8"/>
                    <measurement group_id="O6" value="-24.9" spread="20.0"/>
                    <measurement group_id="O7" value="-27.5" spread="28.4"/>
                    <measurement group_id="O8" value="-34.4" spread="34.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>All questions</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>A standard deviation of 14 was assumed based on pilot data and the non-inferiority delta was set to 7. The chosen sample size and alpha = 0.025 provides 80% power for this endpoint</non_inferiority_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-3.08</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.89</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.75</ci_lower_limit>
            <ci_upper_limit>2.59</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Pain Score During Treatment</title>
        <description>The patient placed a vertical line on visual analog scale questionnaire using a scale of 0-100 (0 = no pain, 100 = maximum pain) at the point that indicated the pain in or around their eyelids, or face during the procedure including feelings of pressure, tightness, heaviness, burning, and other negative sensations. A score a 20 was associated with a description of &quot;hurts a little&quot;. Assessments were made at baseline (pre-treatment), immediately post-treatment, and Day 1 post-treatment. No formal hypothesis testing was pre-specified for this endpoint.</description>
        <time_frame>Baseline (Day 0), Immediately Post-Treatment (Day 0), Day 1 Post-Treatment</time_frame>
        <population>All randomized and treated patients</population>
        <group_list>
          <group group_id="O1">
            <title>iLux Right Eye</title>
            <description>Right Eye of Subjects treated with the iLux 2020 System</description>
          </group>
          <group group_id="O2">
            <title>iLux Left Eye</title>
            <description>Left Eye of Subjects treated with the iLux 2020 System</description>
          </group>
          <group group_id="O3">
            <title>iLux Both Eyes</title>
            <description>Both Eyes of Subjects treated with the iLux 2020 System</description>
          </group>
          <group group_id="O4">
            <title>LipiFlow Right Eye</title>
            <description>Right Eye of Subjects Treated with the LipiFlow Thermal Pulsation System</description>
          </group>
          <group group_id="O5">
            <title>LipiFlow Left Eye</title>
            <description>Left Eye of Subjects treated with Lipiflow Thermal Pulsation System</description>
          </group>
          <group group_id="O6">
            <title>LipiFlow Both Eyes</title>
            <description>Both Eyes of Subjects treated with the LipiFlow Thermal Pulsation System</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Pain Score During Treatment</title>
          <description>The patient placed a vertical line on visual analog scale questionnaire using a scale of 0-100 (0 = no pain, 100 = maximum pain) at the point that indicated the pain in or around their eyelids, or face during the procedure including feelings of pressure, tightness, heaviness, burning, and other negative sensations. A score a 20 was associated with a description of &quot;hurts a little&quot;. Assessments were made at baseline (pre-treatment), immediately post-treatment, and Day 1 post-treatment. No formal hypothesis testing was pre-specified for this endpoint.</description>
          <population>All randomized and treated patients</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="71"/>
                <count group_id="O3" value="71"/>
                <count group_id="O4" value="69"/>
                <count group_id="O5" value="70"/>
                <count group_id="O6" value="70"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="71"/>
                <count group_id="O3" value="142"/>
                <count group_id="O4" value="69"/>
                <count group_id="O5" value="70"/>
                <count group_id="O6" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Day 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.4" spread="28.6"/>
                    <measurement group_id="O2" value="34.0" spread="28.0"/>
                    <measurement group_id="O3" value="34.2" spread="28.2"/>
                    <measurement group_id="O4" value="30.8" spread="26.4"/>
                    <measurement group_id="O5" value="32.6" spread="27.6"/>
                    <measurement group_id="O6" value="31.7" spread="27.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Immediately Post-Treatment (Day 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.2" spread="25.1"/>
                    <measurement group_id="O2" value="23.6" spread="23.7"/>
                    <measurement group_id="O3" value="24.4" spread="24.3"/>
                    <measurement group_id="O4" value="10.2" spread="14.6"/>
                    <measurement group_id="O5" value="10.1" spread="13.8"/>
                    <measurement group_id="O6" value="10.1" spread="14.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 Post-Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.0" spread="15.7"/>
                    <measurement group_id="O2" value="13.0" spread="17.0"/>
                    <measurement group_id="O3" value="12.5" spread="16.3"/>
                    <measurement group_id="O4" value="11.8" spread="17.8"/>
                    <measurement group_id="O5" value="11.5" spread="16.9"/>
                    <measurement group_id="O6" value="11.7" spread="17.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Discomfort Score During Treatment</title>
        <description>The patient placed a vertical line on visual analog scale questionnaire using a scale of 0-100 (0 = no discomfort, 100 = maximum discomfort) at the point that indicated the discomfort in or around their eyelids, or face during the procedure including feelings of pressure, tightness, heaviness, burning, and other negative sensations. Assessments were made at baseline (pre-treatment), immediately post-treatment, and Day 1 post-treatment. No formal hypothesis testing was pre-specified for this endpoint.</description>
        <time_frame>Baseline (Day 0), Immediately Post-Treatment (Day 0), Day 1 Post-Treatment</time_frame>
        <population>All randomized and treated patients</population>
        <group_list>
          <group group_id="O1">
            <title>iLux Right Eye</title>
            <description>Right Eye of Subjects treated with the iLux 2020 System</description>
          </group>
          <group group_id="O2">
            <title>iLux Left Eye</title>
            <description>Left Eye of Subjects treated with the iLux 2020 System</description>
          </group>
          <group group_id="O3">
            <title>iLux Both Eyes</title>
            <description>Both Eyes of Subjects treated with the iLux 2020 System</description>
          </group>
          <group group_id="O4">
            <title>LipiFlow Right Eye</title>
            <description>Right Eye of Subjects Treated with the LipiFlow Thermal Pulsation System</description>
          </group>
          <group group_id="O5">
            <title>LipiFlow Left Eye</title>
            <description>Left Eye of Subjects treated with Lipiflow Thermal Pulsation System</description>
          </group>
          <group group_id="O6">
            <title>LipiFlow Both Eyes</title>
            <description>Both Eyes of Subjects treated with the LipiFlow Thermal Pulsation System</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Discomfort Score During Treatment</title>
          <description>The patient placed a vertical line on visual analog scale questionnaire using a scale of 0-100 (0 = no discomfort, 100 = maximum discomfort) at the point that indicated the discomfort in or around their eyelids, or face during the procedure including feelings of pressure, tightness, heaviness, burning, and other negative sensations. Assessments were made at baseline (pre-treatment), immediately post-treatment, and Day 1 post-treatment. No formal hypothesis testing was pre-specified for this endpoint.</description>
          <population>All randomized and treated patients</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="71"/>
                <count group_id="O3" value="71"/>
                <count group_id="O4" value="69"/>
                <count group_id="O5" value="70"/>
                <count group_id="O6" value="70"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="71"/>
                <count group_id="O3" value="142"/>
                <count group_id="O4" value="69"/>
                <count group_id="O5" value="70"/>
                <count group_id="O6" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Day 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.3" spread="22.3"/>
                    <measurement group_id="O2" value="55.9" spread="21.8"/>
                    <measurement group_id="O3" value="56.1" spread="22.0"/>
                    <measurement group_id="O4" value="52.1" spread="23.6"/>
                    <measurement group_id="O5" value="52.6" spread="24.0"/>
                    <measurement group_id="O6" value="52.3" spread="23.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Immediately Post-Treatment (Day 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.9" spread="24.7"/>
                    <measurement group_id="O2" value="36.7" spread="22.5"/>
                    <measurement group_id="O3" value="37.8" spread="23.6"/>
                    <measurement group_id="O4" value="22.3" spread="21.2"/>
                    <measurement group_id="O5" value="23.7" spread="21.6"/>
                    <measurement group_id="O6" value="23.0" spread="21.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 Post-Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.5" spread="22.5"/>
                    <measurement group_id="O2" value="23.7" spread="22.4"/>
                    <measurement group_id="O3" value="23.6" spread="22.4"/>
                    <measurement group_id="O4" value="24.7" spread="24.2"/>
                    <measurement group_id="O5" value="24.4" spread="23.4"/>
                    <measurement group_id="O6" value="24.5" spread="23.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Post-Treatment in Ocular Surface Staining</title>
        <description>Corneal staining was assessed by the examiner using the National Eye Institute corneal grading scale and a slit-lamp. Each of the 5 corneal regions (superior, inferior, central, temporal, &amp; central), was graded on a 0-3 scale, where 0=normal-no staining (best); 1=mild-superficial stippling micropunctate staining; 2=moderate-macropunctate staining with some coalescent areas; and 3=severe-numerous coalescent macropunctate areas and/or patches (worst). The scores were summed for each eye, and an overall corneal staining score was computed as the average of the sum from both eyes. Overall scores ranged between 0-15, with higher change value indicating greater damage to the corneal surface. Assessments were made at baseline (pre-treatment), immediately post-treatment, and Day 1 post-treatment. No formal hypothesis testing was pre-specified for this endpoint.</description>
        <time_frame>Baseline (Day 0), Immediately Post-Treatment (Day 0), Day 1 Post-Treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>iLux Right Eye</title>
            <description>Right Eye of Subjects treated with the iLux 2020 System</description>
          </group>
          <group group_id="O2">
            <title>iLux Left Eye</title>
            <description>Left Eye of Subjects treated with the iLux 2020 System</description>
          </group>
          <group group_id="O3">
            <title>iLux Both Eyes</title>
            <description>Both Eyes of Subjects treated with the iLux 2020 System</description>
          </group>
          <group group_id="O4">
            <title>LipiFlow Right Eye</title>
            <description>Right Eye of Subjects Treated with the LipiFlow Thermal Pulsation System</description>
          </group>
          <group group_id="O5">
            <title>LipiFlow Left Eye</title>
            <description>Left Eye of Subjects treated with Lipiflow Thermal Pulsation System</description>
          </group>
          <group group_id="O6">
            <title>LipiFlow Both Eyes</title>
            <description>Both Eyes of Subjects treated with the LipiFlow Thermal Pulsation System</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Post-Treatment in Ocular Surface Staining</title>
          <description>Corneal staining was assessed by the examiner using the National Eye Institute corneal grading scale and a slit-lamp. Each of the 5 corneal regions (superior, inferior, central, temporal, &amp; central), was graded on a 0-3 scale, where 0=normal-no staining (best); 1=mild-superficial stippling micropunctate staining; 2=moderate-macropunctate staining with some coalescent areas; and 3=severe-numerous coalescent macropunctate areas and/or patches (worst). The scores were summed for each eye, and an overall corneal staining score was computed as the average of the sum from both eyes. Overall scores ranged between 0-15, with higher change value indicating greater damage to the corneal surface. Assessments were made at baseline (pre-treatment), immediately post-treatment, and Day 1 post-treatment. No formal hypothesis testing was pre-specified for this endpoint.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="71"/>
                <count group_id="O3" value="71"/>
                <count group_id="O4" value="70"/>
                <count group_id="O5" value="70"/>
                <count group_id="O6" value="70"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="71"/>
                <count group_id="O3" value="142"/>
                <count group_id="O4" value="70"/>
                <count group_id="O5" value="70"/>
                <count group_id="O6" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change from Baseline to Immediately Post-Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="1.7"/>
                    <measurement group_id="O2" value="0.6" spread="1.7"/>
                    <measurement group_id="O3" value="0.6" spread="1.7"/>
                    <measurement group_id="O4" value="0.5" spread="1.6"/>
                    <measurement group_id="O5" value="0.4" spread="1.5"/>
                    <measurement group_id="O6" value="0.4" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to Day 1 Post-Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="1.8"/>
                    <measurement group_id="O2" value="-1.0" spread="2.0"/>
                    <measurement group_id="O3" value="-0.9" spread="1.9"/>
                    <measurement group_id="O4" value="-0.9" spread="1.5"/>
                    <measurement group_id="O5" value="-1.2" spread="1.9"/>
                    <measurement group_id="O6" value="-1.1" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Post-Treatment in Intraocular Pressure (IOP)</title>
        <description>IOP (fluid pressure inside the eye) was measured by Goldmann applanation tonometry. A higher IOP can be a greater risk for developing glaucoma or glaucoma progression (leading to optic nerve damage). A negative change value indicates an improvement. No formal hypothesis testing was pre-specified for this endpoint.</description>
        <time_frame>Baseline (Day 0), Immediately Post-Treatment (Day 0)</time_frame>
        <population>All randomized and treated patients</population>
        <group_list>
          <group group_id="O1">
            <title>iLux Right Eye</title>
            <description>Right Eye of Subjects treated with the iLux 2020 System</description>
          </group>
          <group group_id="O2">
            <title>iLux Left Eye</title>
            <description>Left Eye of Subjects treated with the iLux 2020 System</description>
          </group>
          <group group_id="O3">
            <title>iLux Both Eyes</title>
            <description>Both Eyes of Subjects treated with the iLux 2020 System</description>
          </group>
          <group group_id="O4">
            <title>LipiFlow Right Eye</title>
            <description>Right Eye of Subjects Treated with the LipiFlow Thermal Pulsation System</description>
          </group>
          <group group_id="O5">
            <title>LipiFlow Left Eye</title>
            <description>Left Eye of Subjects treated with Lipiflow Thermal Pulsation System</description>
          </group>
          <group group_id="O6">
            <title>LipiFlow Both Eyes</title>
            <description>Both Eyes of Subjects treated with the LipiFlow Thermal Pulsation System</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Post-Treatment in Intraocular Pressure (IOP)</title>
          <description>IOP (fluid pressure inside the eye) was measured by Goldmann applanation tonometry. A higher IOP can be a greater risk for developing glaucoma or glaucoma progression (leading to optic nerve damage). A negative change value indicates an improvement. No formal hypothesis testing was pre-specified for this endpoint.</description>
          <population>All randomized and treated patients</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="71"/>
                <count group_id="O3" value="71"/>
                <count group_id="O4" value="69"/>
                <count group_id="O5" value="69"/>
                <count group_id="O6" value="69"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="71"/>
                <count group_id="O3" value="142"/>
                <count group_id="O4" value="69"/>
                <count group_id="O5" value="69"/>
                <count group_id="O6" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="1.44"/>
                    <measurement group_id="O2" value="-0.07" spread="1.54"/>
                    <measurement group_id="O3" value="-0.01" spread="1.49"/>
                    <measurement group_id="O4" value="0.07" spread="1.94"/>
                    <measurement group_id="O5" value="-0.04" spread="1.79"/>
                    <measurement group_id="O6" value="0.01" spread="1.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Post-Treatment in Best Spectacle-Corrected Visual Acuity (BSCVA)</title>
        <description>Visual acuity was assessed with spectacles or other visual corrective devices in place using Early Treatment Diabetic Retinopathy Study (ETDRS) charts. Results are presented in logarithm of the minimum angle of resolution (logMAR) with 0.2 in logMAR corresponding to 10 ETDRS letters read. A lower logMAR change value indicates an improvement in visual acuity. No formal hypothesis testing was pre-specified for this endpoint.</description>
        <time_frame>Baseline (Day 0), Immediately Post-Treatment (Day 0)</time_frame>
        <population>All randomized and treated patients</population>
        <group_list>
          <group group_id="O1">
            <title>iLux Right Eye</title>
            <description>Right Eye of Subjects treated with the iLux 2020 System</description>
          </group>
          <group group_id="O2">
            <title>iLux Left Eye</title>
            <description>Left Eye of Subjects treated with the iLux 2020 System</description>
          </group>
          <group group_id="O3">
            <title>iLux Both Eyes</title>
            <description>Both Eyes of Subjects treated with the iLux 2020 System</description>
          </group>
          <group group_id="O4">
            <title>LipiFlow Right Eye</title>
            <description>Right Eye of Subjects Treated with the LipiFlow Thermal Pulsation System</description>
          </group>
          <group group_id="O5">
            <title>LipiFlow Left Eye</title>
            <description>Left Eye of Subjects treated with Lipiflow Thermal Pulsation System</description>
          </group>
          <group group_id="O6">
            <title>LipiFlow Both Eyes</title>
            <description>Both Eyes of Subjects treated with the LipiFlow Thermal Pulsation System</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Post-Treatment in Best Spectacle-Corrected Visual Acuity (BSCVA)</title>
          <description>Visual acuity was assessed with spectacles or other visual corrective devices in place using Early Treatment Diabetic Retinopathy Study (ETDRS) charts. Results are presented in logarithm of the minimum angle of resolution (logMAR) with 0.2 in logMAR corresponding to 10 ETDRS letters read. A lower logMAR change value indicates an improvement in visual acuity. No formal hypothesis testing was pre-specified for this endpoint.</description>
          <population>All randomized and treated patients</population>
          <units>logMAR</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="71"/>
                <count group_id="O3" value="71"/>
                <count group_id="O4" value="70"/>
                <count group_id="O5" value="70"/>
                <count group_id="O6" value="70"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="71"/>
                <count group_id="O3" value="142"/>
                <count group_id="O4" value="70"/>
                <count group_id="O5" value="70"/>
                <count group_id="O6" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.08"/>
                    <measurement group_id="O2" value="0.05" spread="0.11"/>
                    <measurement group_id="O3" value="0.03" spread="0.09"/>
                    <measurement group_id="O4" value="0.02" spread="0.11"/>
                    <measurement group_id="O5" value="0.02" spread="0.07"/>
                    <measurement group_id="O6" value="0.02" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 weeks</time_frame>
      <desc>Any untoward and unintended sign, symptom or disease temporally associated with the use of an investigational drug or device, or other protocol-imposed intervention, regardless of the suspected cause. Chronic but stable conditions or diseases are not AEs. Changes in a chronic condition or disease consistent with natural disease progression are not AEs. AEs were assessed during procedure, immediately post-procedure, 1 day, 2 weeks, &amp; 4 weeks post-procedure.</desc>
      <group_list>
        <group group_id="E1">
          <title>iLux 2020 System</title>
          <description>Meibomian Gland Treatment
iLux 2020 System: Heating and compression to express clogged meibomian glands</description>
        </group>
        <group group_id="E2">
          <title>LipiFlow Thermal Pulsation System</title>
          <description>Meibomian Gland Treatment
LipiFlow Pulsation System: Heating and compression to express clogged meibomian glands</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <description>Includes: burning sensation, itching, stinging, petechial hemorrhage, superficial punctate keratitis, and blurred vision</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="71"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Rob Thornhill</name_or_title>
      <organization>TearFilm Innovations, Inc.</organization>
      <phone>844-458-9776</phone>
      <email>rthornhill@tearfilm.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

